相关实验视频

Updated: Jul 11, 2025

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

硫酸盐和阿尔茨海默病之间的双向联系

Valerie Christin Zimmer¹, Anna Andrea Lauer², Viola Haupenthal¹

¹Deutsches Institut für Demenzprävention (DIDP), Neurodegeneration and Neurobiology and Experimental Neurology, Saarland University, 66424 Homburg/Saar, Germany.

Cell chemical biology

|November 16, 2023

概括

阿尔茨海默病与减少的硫酸盐有关. 粉样蛋白前体蛋白加工会影响硫酸盐的含量,而硫酸盐反过来会减少粉样β生成,这表明硫酸盐在阿尔茨海默氏症中具有关键作用.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
分子生物学分子生物学

背景情况:

在阿尔茨海默病 (AD) 患者中观察到硫酸盐水平降低.
在AD病变发生过程中,粉样前体蛋白 (APP) 处理和硫酸盐代谢之间的相互作用尚未完全理解.

研究的目的:

阐明APP加工和硫酸盐合成之间的双向监管关系.
研究调节AD中硫酸盐水平的治疗潜力.

主要方法:

利用细胞培养和转基因小鼠模型与改变的APP处理.
评估了APP细胞内域 (AICD) 对Gal3st1/CST表达和硫酸盐合成的影响.
研究了硫酸盐补充剂对粉样β (Aβ) 生成和分泌酶活性 (BACE1,γ-分泌酶) 的影响.
从AD患者和相关动物模型中分析了大脑样本.

主要成果:

发现APP细胞内域 (AICD) 降低了Gal3st1/CST表达,导致硫酸盐合成减少.
硫酸盐补充剂通过抑制BACE1和γ-分泌酶活性来降低Aβ生成.
降低BACE1水平与增加的溶酶体降解有关,而降低的γ-分泌酶活性则是直接影响和脂质中的成分水平变化的结果.
甲基硫酸酶A或Gal3st1/CST的缺乏反映了这些变化.
硫酸盐降低了阿尔茨海默病患者的大脑同质化的g-分泌酶活性.
在人类大脑APP水平和GAL3ST1/CST表达之间观察到负相关性.

结论:

在阿尔茨海默病中,APP处理和硫酸盐平衡之间存在关键的反循环.
调节硫酸盐含量是一个潜在的治疗策略,可以减少AD中的Aβ病理.

关键词:

APP细胞间域 APP细胞间域阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉样蛋白前体蛋白加工粉样蛋白前体蛋白加工一个Aβ生成的Aβ.加尔3st1 /CST7) 的情况.脂质的恒常性脂质的恒常性脂质漂泊船是指脂质漂泊船,是指脂质漂泊船.硫酸硫化物是一种硫化物.这是一种β-分泌酶.γ-秘密的秘密

更多相关视频

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...